Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
SYSpyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. (SYRE)

NASDAQ Capital Market · Currency in USD
$90.33 ▼ -2.00 (-2.17%)
At close: Oct 23, 4:00 PM ET. Market closed.
$90.33 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$92.33
Open
$91.90
Day's Range
$88.78 – $92.50
52 Week Range
$21.15 – $110.18
Volume
503,013
Avg. Volume
1,357,904
Market Cap
$8.34B
Beta (5Y Monthly)
3.11
PE Ratio (TTM)
--
EPS (TTM)
-$2.11
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$119.89

Profile: Spyre Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
125
CEO
Cameron Turtle
Website
spyre.com

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.78
DateEst.Actual
Aug 4, 2026-$0.76-$0.36Beat
May 5, 2026-$0.66-$0.74Miss
Feb 19, 2026-$0.66-$0.70Miss
Nov 4, 2025-$0.76-$0.15Beat
Aug 5, 2025-$0.73-$0.49Beat
May 8, 2025-$0.84-$0.74Beat

Analyst view

Consensus price target
$119.89 ▲ +32.7%
Range $107.00 – $130.00
Rating: Buy
Buy 92% · Hold 8% · Sell 0%

Get free alerts on SYRE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.